Literature DB >> 22367584

Nesfatin-1 and other hormone alterations in polycystic ovary syndrome.

Rulin Deniz1, Bilgin Gurates, Suleyman Aydin, Husnu Celik, Ibrahim Sahin, Yakup Baykus, Zekiye Catak, Aziz Aksoy, Cihan Citil, Sami Gungor.   

Abstract

Polycystic ovary syndrome (PCOS) is commonly characterised by obesity, insulin resistance (IR), hyperandrogenemia and hirsutism. Nesfatin-1 a recently discovered hormone, acts upon energy balance, glucose metabolism, obesity and probably gonadal functions. This study was to evaluate the circulating levels of nesfatin-1 in patients with PCOS (n = 30) and in age and body mass index (BMI)-matched controls (n = 30). PCOS patients had significantly lower levels of nesfatin-1 (0.88 ± 0.36 ng/mL) than healthy controls (2.22 ± 1.14 ng/mL). PCOS patients also had higher gonadotropin and androgen plasma concentrations, Ferriman-Gallwey scores, blood glucose levels and a homeostasis model of assessment-IR index (HOMA-IR) index than in healthy women. Correlation tests in PCOS subjects detected a negative correlation between nesfatin-1 levels and BMI, fasting blood glucose, insulin levels and a HOMA-IR index. Lower nesfatin-1 concentration may plays a very important role in the development of PCOS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367584     DOI: 10.1007/s12020-012-9638-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  35 in total

1.  A 20-year follow-up of young women with polycystic ovary syndrome.

Authors:  Enrico Carmina; Anna Maria Campagna; Roger A Lobo
Journal:  Obstet Gynecol       Date:  2012-02       Impact factor: 7.661

Review 2.  Insulin resistance in polycystic ovary syndrome: progress and paradoxes.

Authors:  A M Venkatesan; A Dunaif; A Corbould
Journal:  Recent Prog Horm Res       Date:  2001

3.  Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries.

Authors:  D Dewailly; H Gronier; E Poncelet; G Robin; M Leroy; P Pigny; A Duhamel; S Catteau-Jonard
Journal:  Hum Reprod       Date:  2011-09-16       Impact factor: 6.918

4.  Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.

Authors:  Didier Dewailly; Pascal Pigny; Benoît Soudan; Sophie Catteau-Jonard; Christine Decanter; Edouard Poncelet; Alain Duhamel
Journal:  J Clin Endocrinol Metab       Date:  2010-07-07       Impact factor: 5.958

5.  Identification of nesfatin-1 as a satiety molecule in the hypothalamus.

Authors:  Shinsuke Oh-I; Hiroyuki Shimizu; Tetsurou Satoh; Shuichi Okada; Sachika Adachi; Kinji Inoue; Hiroshi Eguchi; Masanori Yamamoto; Toshihiro Imaki; Koushi Hashimoto; Takafumi Tsuchiya; Tsuyoshi Monden; Kazuhiko Horiguchi; Masanobu Yamada; Masatomo Mori
Journal:  Nature       Date:  2006-10-01       Impact factor: 49.962

Review 6.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

7.  Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment.

Authors:  Bee K Tan; Manfred Hallschmid; Werner Kern; Hendrik Lehnert; Harpal S Randeva
Journal:  J Clin Endocrinol Metab       Date:  2011-01-20       Impact factor: 5.958

8.  Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans.

Authors:  Qing-Chun Li; Hai-Yan Wang; Xi Chen; Hong-Zai Guan; Zheng-Yao Jiang
Journal:  Regul Pept       Date:  2010-01-08

Review 9.  Nesfatin-1: an overview and future clinical application.

Authors:  Hiroyuki Shimizu; Sinsuke Oh-I; Shuichi Okada; Masatomo Mori
Journal:  Endocr J       Date:  2009-05-20       Impact factor: 2.349

Review 10.  Assessment of glucose intolerance and insulin sensitivity in polycystic ovary syndrome.

Authors:  Bulent O Yildiz; Olcay Gedik
Journal:  Reprod Biomed Online       Date:  2004-06       Impact factor: 3.828

View more
  16 in total

Review 1.  Nesfatin-1 and its effects on different systems.

Authors:  C Ayada; Ü Toru; Y Korkut
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

2.  Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome.

Authors:  Esra Nur Ademoglu; Suheyla Gorar; Ayse Carlıoglu; Havva Yazıcı; Fatma Dilek Dellal; Zehra Berberoglu; Derya Akdeniz; Sema Uysal; Feridun Karakurt
Journal:  J Endocrinol Invest       Date:  2014-06-12       Impact factor: 4.256

Review 3.  Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.

Authors:  Dimitrios Panidis; Konstantinos Tziomalos; Efstathios Papadakis; Christos Vosnakis; Panagiotis Chatzis; Ilias Katsikis
Journal:  Endocrine       Date:  2013-04-27       Impact factor: 3.633

Review 4.  Gastrointestinal hormones and polycystic ovary syndrome.

Authors:  Jing Ma; Tzu Chun Lin; Wei Liu
Journal:  Endocrine       Date:  2014-05-04       Impact factor: 3.633

Review 5.  Multi-functional peptide hormone NUCB2/nesfatin-1.

Authors:  Suleyman Aydin
Journal:  Endocrine       Date:  2013-03-23       Impact factor: 3.633

6.  Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome.

Authors:  Peng Shen; Yingying Han; Bo Cai; Yu Wang
Journal:  Sleep Breath       Date:  2014-07-24       Impact factor: 2.816

Review 7.  Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.

Authors:  Sandra Feijóo-Bandín; Diego Rodríguez-Penas; Vanessa García-Rúa; Ana Mosquera-Leal; José Ramón González-Juanatey; Francisca Lago
Journal:  Endocrine       Date:  2015-12-12       Impact factor: 3.633

8.  The Relationship between Nesfatin-1 Levels and SYNTAX Score in Patients with Non-ST Segment Elevation Myocardial Infarction.

Authors:  Mevlüt Serdar Kuyumcu; Aliye Kuyumcu; Çağrı Yayla; Mustafa Bilal Özbay; Sefa Ünal; Burak Açar; Cemil Nural; Almila Şenat; Gülhan Samur
Journal:  Acta Cardiol Sin       Date:  2018-09       Impact factor: 2.672

9.  Assessment of FSHR, AMH, and AMHRII variants in women with polycystic ovary syndrome.

Authors:  Ewa Czeczuga-Semeniuk; Katarzyna Jarząbek; Marzenna Galar; Piotr Kozłowski; Nela A Sarosiek; Gabriela Zapolska; Sławomir Wołczyński
Journal:  Endocrine       Date:  2014-07-11       Impact factor: 3.633

10.  Acylated and desacylated ghrelin, preptin, leptin, and nesfatin-1 Peptide changes related to the body mass index.

Authors:  Yusuf Ozkan; Esra Suay Timurkan; Suleyman Aydin; Ibrahim Sahin; Mustafa Timurkan; Cihan Citil; Mehmet Kalayci; Musa Yilmaz; Aziz Aksoy; Zekiye Catak
Journal:  Int J Endocrinol       Date:  2013-11-25       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.